High doses, repeated administration, vulnerable populations (pregnant animals), and sensitive tissues (gastrointestinal tract, reproductive organs) have all been evaluated

Amylin/Calcitonin Receptor Agonism (cagrilintide) Delays gastric emptying, reduces postprandial glucagon, and strongly promotes satiety Modulates appetite-regulating centers in the hindbrain, hypothalamus, and brain reward circuits, directly influencing food intake and choice May transiently activate the renin-angiotensin-aldosterone system with dose escalation, but without blood pressure or electrolyte derangements GLP-1 Receptor Agonism (semaglutide) Stimulates glucose-dependent insulin secretion and suppresses glucagon release to improve glycemic control Reduces appetite and ad libitum energy intake, with central effects on GLP-1R-expressing nuclei in hypothalamus and brainstem Delays gastric emptying and increases satiety, contributing to progressive bodyweight loss Pharmacokinetic Profile Route of Administration Subcutaneous Dosing Frequency Once weekly Route of Administration : Subcutaneous Injection Dosing Frequency: Once weekly Half -life: Cagrilintide: 7-8 days

BPC-157 supports soft tissue repair, including muscles, tendons, and ligaments, and has shown promise in tendon healing, muscle growth, and helping to reduce inflammation
The one cancer signal in the literature is not reassuring : in a study of gastrointestinal stromal tumors, higher levels of thymosin beta-4 tracked with more aggressive disease and worse outcomes
Neither tab is a human dosing recommendation